In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
<iframe src="https://hindustansphere.com/embed/cluster/04b6cf1b89cedf7c1bec9226d4117266381cb54a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz"></iframe>
